However, among Taiwanese NSCLC patients, a much lower prevalence of KRAS mutation is observed, with only 7.7% having any KRAS mutation and 2.5% of all cases with KRAS G12C [18]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.